IDEAYA's 'first patient in' is a real milestone - but upstream flags instrument tradeability issues, so you cannot express it cleanly here
The Opportunity
Upstream direction is LONG and the mechanism is the standard biotech one: a dated operational milestone tightens the perceived timeline to the first meaningful data, and markets often re-rate timeline confidence before efficacy arrives. The reason this is AVOID in this layer is not thesis quality; it is that upstream explicitly flags the signal as non-tradeable despite a ticker being present, so the system is telling you the mapping is not reliable enough to treat as an instrument-level call in this output.
The Timing
Freshness is strong at 80 with no staleness flag, but trade confidence is only 47 and the market regime is crosswind-heavy. For this to become actionable, the missing piece is a clean instrument binding in upstream (and ideally independent confirmation via trial registry updates or broader coverage). Until that mapping is resolved, the correct behaviour is to treat this as a live catalyst note rather than a trade ticket generated by this report.
The Evidence
The dated milestone surfaced in upstream due diligence is a 'first patient in' announcement for IDE034 with an observed date of 2026-02-25 ( seekingalpha.com ). The upstream synthesis explicitly notes that this is not a readout; it is an operational start that can tighten timelines but does not resolve probability of success.